Alzheon: Funding, Investors & Team (Sep 2026)
Alzheon is a biotechnology company that specializes in brain health, memory, and aging in women and children. They are working on creating groundbreaking treatments for Alzheimer's disease and other neurodegenerative conditions. Their goal is to develop new drugs that can help prevent cognitive and functional decline in patients affected by these disorders. Alzheon has a unique capability to make significant progress in the complex field of therapeutics for Alzheimer's and similar conditions.
Alzheon has raised $169M across 4 funding rounds on record, the most recent a Series E of $100M announced in Jun 2024.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Alzheon Company Profile and Key Stats
Latest funding round on record: Jun 2024.
Alzheon Funding Rounds
Alzheon raised $50.0M in a Series D announced in Apr 2022.
9 months later, an undisclosed round of $1.7M was announced in Jan 2023.
1.2 years later, an undisclosed round of $17.2M was announced in Mar 2024.
3 months later, a Series E of $100M was announced in Jun 2024.
Alzheon Founders and Leadership Team
Contact details for the Alzheon team: 1 of 1 has an email address on file.
Start 14-day free trial →Alzheon Funding Compared to Other Biotechnology Startups
Alzheon's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Alzheon in Biotechnology and Lexington
Companies Similar to Alzheon
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Paterna BioSciences, Inc. is a pioneering biotechnology company dedicated to solving the significant…
Legendary Bio's solidarity is a determined spotlight on introducing another period of quality guideline.
Cataract surgery is the single most common procedure performed in the United States annually. Despite…
InSitu Biologics is a developer of a drug delivery platform designed to focus on development of new and…
Remedium Bio is a gene therapy company in the Boston area that is dedicated to developing cures for severe…
Alzheon Funding FAQs
What does Alzheon do?
Alzheon is a biotechnology company that specializes in brain health, memory, and aging in women and children. They are working on creating groundbreaking treatments for Alzheimer's disease and other neurodegenerative conditions. Their goal is to develop new drugs that can help prevent cognitive and functional decline in patients affected by these disorders. Alzheon has a unique capability to make significant progress in the complex field of therapeutics for Alzheimer's and similar conditions.
How much funding has Alzheon raised?
Alzheon has raised $169M across 4 rounds on record. The most recent is a Series E of $100M announced in Jun 2024.
When did Alzheon last raise funding?
Alzheon's most recent funding round on record is a Series E of $100M, announced in Jun 2024.
Who founded Alzheon?
FundedIQ lists Martin Tolar (Founder) at Alzheon.
Where is Alzheon headquartered?
Alzheon is based in Lexington, Massachusetts, United States.
How many employees does Alzheon have?
Alzheon is in the 11-50 employee band.
How does Alzheon's funding compare to other Biotechnology startups?
Alzheon's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Alzheon Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Alzheon is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.